HK Stock Market Move | Guangzhou Baiyunshan Pharmaceutical Holdings (00874) fell nearly 6% after earnings as R&D expenses significantly increased, and net profit in the first half of the year dropped by 16.7% year-on-year.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) dropped nearly 6% after its earnings report, and as of the time of writing, it was down 5.64%, trading at HKD 14.22, with a transaction volume of HKD 61.6266 million. In terms of news, Guangzhou Baiyunshan Pharmaceutical Holdings announced its interim results, with operating revenue of RMB 42.091 billion, a slight year-on-year increase of 0.6%; net profit attributable to shareholders was RMB 2.096 billion, a year-on-year decrease of 16.7%. The profit pressure in the first half of the year was partly attributed to strategic adjustments. The companys research and development expenditure increased by 20.36% year-on-year in the first half, striving to create a second growth curve through technological innovation, exchanging short-term pain for long-term core competitiveness. The financial report shows that in terms of research and development, Guangzhou Baiyunshan Pharmaceutical Holdings focuses on five key areas: malignant tumors, chronic disease management, respiratory health, immune system, and urology. It has over 160 ongoing research projects, including 11 first-class innovative drugs, with 2 in Phase I clinical trials, 4 in Phase II clinical trials, and 1 in the marketing authorization application stage. Additionally, the subsidiary Wanglaoji, which primarily operates in the natural beverage sector, continues to accelerate its internationalization efforts.